EUVIMEDEUVIMED entdecken
Open Access

Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study

Ahmed Arafa, Yuka Kato, Yoshihiro Kokubo, Paramita Khairan, Chisa Matsumoto, Yoko M Nakao, Yu Kataoka, Mariko Harada-Shiba

Journal of Atherosclerosis and Thrombosis · 2025

DOI: 10.5551/jat.65437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Atherosclerosis and Thrombosis, 2025. Verfasst von Ahmed Arafa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Cardiology, National Cerebral and Cardiovascular Center. Hauptthemen laut MEDLINE: Lipoprotein(a), Stroke, Coronary Disease, Biomarkers. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Lipoprotein(a) (Lp[a]) exhibits atherogenic and thrombogenic properties. We investigated the association between Lp(a) levels and the risk of coronary heart disease (CHD) and stroke. METHODS: We used data from 5138 people ≥ 30 years old registered in the Suita Study, a Japanese population-based prospective cohort study. All participants were initially free from CHD or stroke. Cox proportional hazard models were applied to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for CHD and stroke among participants with elevated Lp(a) levels. RESULTS: At baseline, only 17.0% of participants had Lp(a) levels ≥ 30 mg/dL. Within the median follow-up period of 11.7 years, 164 CHD and 234 stroke events were detected. In the multivariable-adjusted regression model, Lp(a) ≥ 30 mg/dL was associated with an increased risk of CHD (HR, 1.52 [95% CI, 1.05-2.21]). Every 10-ml/dL increment in Lp(a) level was associated with a 7.9% increase in CHD risk. The association with CHD did not change significantly after adjusting for total cholesterol level or lipid-lowering drugs. In contrast, increased Lp(a) levels were not associated with stroke risk or any subtype. CONCLUSIONS: Lp(a) ≥ 30 mg/dL was associated with an increased risk of CHD in the Japanese population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)StrokeCoronary DiseaseBiomarkersHumansMaleFemaleMiddle AgedProspective StudiesJapanRisk FactorsFollow-Up StudiesAgedAdultPrognosisProportional Hazards Models

Stichwörter der Autor:innen

Coronary heart diseaseLipoprotein(a)Prospective cohort studyStroke

Substanzen

Lipoprotein(a)Biomarkers

Autor:innen und Institutionen

  • Department of Preventive Cardiology, National Cerebral and Cardiovascular Center.
  • Department of Public Health, Faculty of Medicine, Beni-Suef University.
  • Division of Health Sciences, Osaka University Graduate School of Medicine.
  • Department of Internal Medicine, Faculty of Medicine, Universitas Muhammadiyah Jakarta.
  • Department of Cardiology, Center for Health Surveillance and Preventive Medicine, Tokyo Medical University Hospital.
  • Department of Cardiology, National Cerebral and Cardiovascular Center.

Zitieren

APA

Arafa, A., Kato, Y., Kokubo, Y., Khairan, P., Matsumoto, C., M Nakao, Y., Kataoka, Y., & Harada-Shiba, M. (2025). Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.65437

Vancouver

Arafa A, Kato Y, Kokubo Y, Khairan P, Matsumoto C, M Nakao Y, et al. Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study. Journal of Atherosclerosis and Thrombosis. 2025. doi:10.5551/jat.65437

BibTeX
@article{Arafa2025,
  author = {Arafa, Ahmed and Kato, Yuka and Kokubo, Yoshihiro and Khairan, Paramita and Matsumoto, Chisa and M Nakao, Yoko and Kataoka, Yu and Harada-Shiba, Mariko},
  title = {Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2025},
  doi = {10.5551/jat.65437}
}
Kostenlos starten →